23 results
424B5
RPHM
Reneo Pharmaceuticals Inc
13 Nov 23
Prospectus supplement for primary offering
4:58pm
compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive … of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation. We will be able to take advantage of the scaled
424B5
7wpqp0946zfi
4 May 23
Prospectus supplement for primary offering
5:15pm
424B5
oo70pmjv43eztoq
3 May 23
Prospectus supplement for primary offering
4:20pm
S-3
g5fy83hve09b46dvia6y
2 May 22
Shelf registration
4:46pm
DEF 14A
puhs96zc
22 Apr 22
Definitive proxy
4:05pm
10-K
2zqtjp4ri17xki x5fat
23 Mar 22
Annual report
4:38pm
10-Q
boclgar05a9n yhqd
20 May 21
Quarterly report
7:00am